47 ud af 47 tidsskrifter valgt, søgeord (tuberculosis, tuberkulose) valgt, emner højest 30 dage gamle, sorteret efter nyeste først.
47 emner vises.
1
Death after cure: mortality among pulmonary tuberculosis survivors in rural Uganda
Joseph Baruch Baluku, Brenda Namanda, Sharon Namiiro, Diana Karungi Rwabwera, Gloria Mwesigwa, Catherine Namaara, Bright Twinomugisha, Isabella Nyirazihawe, Edwin Nuwagira, Grace Kansiime, Enock Kizito, Mary G. Nabukenya-Mudiope, Moorine Penninah Sekadde, Felix Bongomin, Joshua Senfuka, Ronald Olum, Aggrey Byaruhanga, Ian Munabi, Sarah Kiguli
International Journal of Infectious Diseases, 21.04.2024
Tilføjet 21.04.2024
There were an estimated 155 million tuberculosis (TB) survivors globally as of 2020 [1]. However, the risk of mortality among TB survivors is thrice that of people who have never suffered TB [2]. Early identification of risk factors for long-term mortality in people with TB, especially in rural areas where studies have found a four-fold increase in mortality, could significantly improve their long-term survival [3]. This study aimed to determine the incidence and predictors of mortality among TB survivors at a rural tertiary hospital in Uganda.
Læs mere
Tjek på PubMed
2
For Tuberculosis, Not “To Screen or Not to Screen?” but “Who?” and “How?”
Clinical Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Abstract Active case finding leveraging new molecular diagnostics and chest X-rays with automated interpretation algorithms is increasingly being developed for high-risk populations to drive down tuberculosis incidence. We consider why such an approach did not deliver a decline in tuberculosis prevalence in Brazilian prison populations and what to consider next.
Læs mere
Tjek på PubMed
3
Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection
Journal of Infectious Diseases, 20.04.2024
Tilføjet 20.04.2024
Abstract Background Flu-like reactions can occur after exposure to rifampin, rifapentine, or isoniazid. Prior studies have reported the presence of antibodies to rifampin, but associations with underlying pathogenesis are unclear.Methods We evaluated PREVENT TB study participants who received weekly isoniazid + rifapentine for 3 months (3HP) or daily isoniazid for 9 months (9H) as treatment for M. tuberculosis infection. Flu-like reaction was defined as a grade ≥2 of any of flu-like symptoms. Controls (3HP or 9H) did not report flu-like reactions. We developed a competitive enzyme-linked immunosorbent assays (ELISA) to detect antibodies against rifapentine, isoniazid, rifampin, and rifapentine metabolite.Results Among 128 participants, 69 received 3HP (22 with flu-like reactions; 47 controls) and 59 received 9H (12 with flu-like reactions; 47 controls). In participants receiving 3HP, anti-rifapentine IgG was identified in 2/22 (9%) participants with flu-like reactions and 6/47 (13%) controls (P = 0.7), anti-isoniazid IgG in 2/22 (9%) participants with flu-like reactions and 4/47 (9%) controls (P = 0.9), and anti-rifapentine metabolite IgG in 2/47 (4%) controls (P = 0.9). Among participants receiving 9H, IgG and IgM anti-isoniazid antibodies were each present in 4/47 (9%) controls, respectively, but none among participants with flu-like reactions; anti-rifapentine IgG antibodies were not present in any participants with flu-like reactions or controls.Conclusions We detected anti-rifapentine, anti-isoniazid, and anti-rifapentine metabolite antibodies, but the proportions of participants with antibodies were low, and did not differ between participants with flu-like reactions and those without such reactions. This suggests that flu-like reactions associated with 3HP and 9H were not antibody-mediated.
Læs mere
Tjek på PubMed
4
Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for Deisolation in Community Settings
Clinical Infectious Diseases, 18.04.2024
Tilføjet 18.04.2024
5
NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings
Clinical Infectious Diseases, 18.04.2024
Tilføjet 18.04.2024
6
Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review
Clinical Infectious Diseases, 18.04.2024
Tilføjet 18.04.2024
Abstract Background Outbreaks of vaccine preventable diseases (VPDs) in health care workers (HCWs) can result in morbidity and mortality and cause significant disruptions to health care services, patients and visitors as well as an added burden on the health system. This scoping review is aimed to describe the epidemiology of VPD outbreaks in HCW, caused by diseases which are prevented by the ten vaccines recommended by World Health Organization (WHO) for HCWs.Methods In April 2022 CINAHL, MEDLINE, Global Health and EMBASE were searched for all articles reporting on VPD outbreaks in HCWs since the year 2000. Articles were included regardless of language and study type. Clinical and epidemiological characteristics of VPD outbreaks were described.Results Our search found 9363 articles, of which 216 met inclusion criteria. Studies describing six of the ten VPDs were found: influenza, measles, varicella, tuberculosis, pertussis and rubella. Most articles (93%) were from high- and upper middle-income countries. While most outbreaks occurred in hospitals, several influenza outbreaks were reported in long term care facilities. Based on available data, vaccination rates amongst HCWs were rarely reported.Conclusion We describe several VPD outbreaks in HCWs from 2000 to April 2022. The review emphasises the need to understand the factors influencing outbreaks in HCWs and highlight importance of vaccination amongst HCWs.
Læs mere
Tjek på PubMed
7
Implementation of a rapid diagnostic assay package for cryptococcosis, histoplasmosis and tuberculosis in people living with HIV in Paraguay
BMC Infectious Diseases, 17.04.2024
Tilføjet 17.04.2024
Abstract Background Opportunistic infections (OIs) are common causes of mortality among people living with HIV (PLHIV). We determined prevalence and 30-day mortality due to histoplasmosis, cryptococcosis, and TB in PLHIV with advanced HIV disease (AHD). Methods PLHIV 18 years and older, with a CD4 + T-cell count of less than 350 cells/mm3 newly diagnosed with HIV infection or re-engaged in care after being without ART for more than 90 days (Group A). The second group included symptomatic PLHIV regardless of ART status or CD4 + T-cell count (Group B); all followed for 30 days. Detection of Histoplasma Ag (HisAg) in urine was done by enzyme immunoassay (EIA), Cryptococcus antigen (CrAg) was detected in serum and cerebrospinal fluid (CSF) specimens by lateral flow assay (LFA), and lipoarabinomannan (LAM) detection in urine was by LFA (TB LAM) and in sputum by GeneXpert for diagnosis of Mycobacterium infections. Results From August 2021 to June 2022, 491 PLHIV were enrolled; 482 (98%) had a CD4 + T-cell result, and 381 patients (79%) were classified with AHD according to CD4 + T-cell count (
Læs mere
Tjek på PubMed
8
A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis
BMC Infectious Diseases, 16.04.2024
Tilføjet 16.04.2024
Abstract Background Tuberculosis (TB) ranks as the second leading cause of death globally among all infectious diseases. This problem is likely due to the lack of biomarkers to differentiate the heterogeneous spectrum of infection. Therefore, the first step in solving this problem is to identify biomarkers to distinguish the different disease states of an individual and treat them accordingly. Circulating microRNA (miRNA) biomarkers are promising candidates for various diseases. In fact, we are yet to conceptualize how miRNA expression influences and predicts TB disease outcomes. Thus, this systematic review and meta-analysis aimed to assess the diagnostic efficacy of circulating miRNAs in Latent TB (LTB) and Active Pulmonary TB (PTB). Methods Literature published between 2012 and 2021 was retrieved from PubMed, Web of Science, Cochrane, Scopus, Embase, and Google Scholar. Articles were screened based on inclusion and exclusion criteria, and their quality was assessed using the QUADAS-2 tool. Funnel plots and forest plots were generated to assess the likelihood of study bias and heterogeneity, respectively. Results After the screening process, seven articles were selected for qualitative analysis. The study groups, which consisted of Healthy Control (HC) vs. TB and LTB vs. TB, exhibited an overall sensitivity of 81.9% (95% CI: 74.2, 87.7) and specificity of 68.3% (95% CI: 57.8, 77.2), respectively. However, our meta-analysis results highlighted two potentially valuable miRNA candidates, miR-197 and miR-144, for discriminating TB from HC. The miRNA signature model (miR197-3p, miR-let-7e-5p, and miR-223-3p) has also been shown to diagnose DR-TB with a sensitivity of 100%, but with a compromised specificity of only 75%. Conclusion miRNA biomarkers show a promising future for TB diagnostics. Further multicentre studies without biases are required to identify clinically valid biomarkers for different states of the TB disease spectrum. Systematic review registration PROSPERO (CRD42022302729).
Læs mere
Tjek på PubMed
9
Increased tuberculosis case detection in Tanzanian children and adults using African giant pouched rats
BMC Infectious Diseases, 16.04.2024
Tilføjet 16.04.2024
Abstract Background African giant pouched rats, trained by Anti-Persoonsmijnen Ontmijnende Product Ontwikkeling (APOPO), have demonstrated their ability to detect tuberculosis (TB) from sputum. We assessed rat-based case detection and compared the mycobacterium bacillary load (MTB-load) in children versus adults. Methods From January–December 2022, samples were collected prospectively from 69 Directly Observed Therapy (DOT) facilities’ presumed TB patients. Using an average of five rats, APOPO re-evaluated patients with bacteriologically negative (sputum-smear microscopy or Xpert MTB/RIF) results. Rat-positive samples were tested using concentrated smear light-emitting diode microscopy to confirm TB detection before treatment initiation. The rats’ identification of pulmonary TB is based on smelling TB-specific volatile organic compounds (VOCs) in sputum. Using STATA, Chi-square for odds ratio and confidence interval was calculated and evaluated: (1) the yield of rat-based TB detection compared to that of the health facilities; (2) rat-based TB detection in children versus adults; and (3) rats’ ability to detect TB across MTB-loads and between children and adults. Results From 35,766 patients, 5.3% (1900/35,766) were smear-positive and 94.7% (33,866/35,766) were smear or Xpert-negatives at DOTS facility. Of those with negative results, 2029 TB cases were detected using rats, contributing to 52% (2029/3929 of total TB identified), which otherwise would have been missed. Compared to DOT facilities, rats were six-fold more likely to detect TB among Acid Fast Bacilli (AFB) 1+/scanty [90% (1829/2029) versus 60% (1139/1900), odds ratio, OR = 6.11, 95% confidence interval, CI: 5.14–7.26]; twice more likely to identify TB cases among children [71% (91/129) versus 51% (1795/3542), OR = 2.3, 95% CI: 1.59–3.42]; and twice more likely to identify TB cases among children with AFB 1+/scanty than adults with the same MTB-load [5% (86/1703) versus 3% (28/1067), OR = 2.0, 95% CI: 1.28–3.03]. Conclusions Rats contributed over half of the TB cases identified in program settings, and children, especially those with a lower MTB-load, were more likely to be diagnosed with TB by rats. The chemical signatures, VOCs, were only available for adults, and further research describing the characteristics of VOCs in children versus adults may pave the way to enhance TB diagnosis in children.
Læs mere
Tjek på PubMed
10
Dual-centre evaluation of the FluoroType MTBDR version 2 assay for detection of Mycobacterium tuberculosis complex and resistance-conferring mutations in pulmonary and extrapulmonary samples from Denmark, Germany and Sierra Leone
Erik Svensson, Hannah Ketelsen, Sönke Andres, Dorte Bek Folkvardsen, Doris Hillemann, Ousman Conteh, Anders Norman, Stefan Niemann, Troels Lillebaek, Martin Kuhns
Clinical Microbiology and Infection, 14.04.2024
Tilføjet 14.04.2024
We evaluated the ability of FluoroType MTBDR version 2 (FTv2; Hain Lifescience), a second-step real-time PCR assay, to simultaneously detect Mycobacterium tuberculosis complex (MTBC) DNA and mutations conferring resistance to rifampicin (RIF) and isoniazid (INH), in pulmonary and extrapulmonary samples from patients and compared them with corresponding cultures.
Læs mere
Tjek på PubMed
11
[Articles] Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Iman Satti, Julia L Marshall, Stephanie A Harris, Rachel Wittenberg, Rachel Tanner, Raquel Lopez Ramon, Morven Wilkie, Fernando Ramos Lopez, Michael Riste, Daniel Wright, Marco Polo Peralta Alvarez, Nicola Williams, Hazel Morrison, Elena Stylianou, Pedro Folegatti, Daniel Jenkin, Samantha Vermaak, Linnea Rask, Ingrid Cabrera Puig, Rebecca Powell Doherty, Alison Lawrie, Paul Moss, Timothy Hinks, Henry Bettinson, Helen McShane
Lancet Infectious Diseases, 13.04.2024
Tilføjet 13.04.2024
This first-in-human aerosol BCG controlled human infection model was sufficiently well tolerated. Further work will evaluate the utility of this model in assessing vaccine efficacy and identifying potential correlates of protection.
Læs mere
Tjek på PubMed
12
Predictors of quality of life of TB/HIV co-infected patients in the Northern region of Ghana
BMC Infectious Diseases, 13.04.2024
Tilføjet 13.04.2024
Abstract Background Tuberculosis (TB) and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) co-morbidity continues to be a serious worldwide health issue, particularly in Sub-Saharan Africa. Studies on the quality of life (QOL) of TB/HIV co-infected patients guide stakeholders on the delivery of patient-centred healthcare. This study evaluated QOL of TB/HIV co-infected individuals and its contributing factors. Methods We conducted a cross-sectional study among TB/HIV co-infected patients, receiving treatment at clinics in the Northern Region of Ghana. Simple random sampling technique was used to select 213 patients from 32 clinics. We gathered information on patients’ QOL using the World Health Organization QOL-HIV BREF assessment tool. At a 5% level of significance, multiple logistic regression analyses were carried out to find correlates of QOL among the patients. Results The mean age of the patients was (38.99 ± 14.00) years with most, 33.3% (71/213) aged 30–39 years. Males constituted 54.9% (117/213). About 30.0% (64/213) of the patients reported a good QOL. Being employed (aOR = 5.23, 95% CI: 1.87 – 14.60), and adhering to treatment (aOR = 6.36, 95% CI: 1.51 – 26.65) were significantly associated with a good QOL. Being depressed (aOR = 0.02, 95% CI: 0.03 – 0.29), stigmatized (aOR = 0.31, 95% CI : 0.11 – 0.84), and not exercising (aOR = 0.28, 95% CI: 0.12 – 0.67) were negatively associated with a good QOL. Conclusion Less than one-third of TB/HIV co-infected patients in the region have good QOL. To guarantee good QOL, modifiable predictors such as patients’ physical activity and medication adherence should be targeted by the National AIDS and TB Control Programs.
Læs mere
Tjek på PubMed
13
Incipient tuberculosis: a comprehensive overview
Infection, 10.04.2024
Tilføjet 10.04.2024
Abstract In the context of the evolving global health landscape shaped by the COVID-19 pandemic, tuberculosis (TB) is gaining renewed attention as a reemerging threat even in low-endemic countries. Immunological tests such as the tuberculin skin test (TST) and interferon-gamma release assay (IGRA) are pivotal in identifying tuberculosis infection (TBI). However, their inability to distinguish between past and ongoing infection poses a diagnostic challenge, possibly leading to the unnecessary treatment of a significant portion of the population with potential side effects. This review delves into the concept of incipient tuberculosis (ITB), a dynamic, presymptomatic stage characterized by heightened Mycobacterium tuberculosis complex (MTC) metabolic activity and replication that result in minimal radiological changes, signifying a transitional state between TBI and TB. Key focus areas include epidemiological factors, underlying pathogenesis, imaging findings, and the ongoing challenges in the identification of individuals with ITB through the development of new biomarkers and the use of whole-genome sequencing-based analyses to implement early treatment strategies.
Læs mere
Tjek på PubMed
14
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis
Allan KengoFirdaus NabeemeeahPaolo DentiRyan SabetGifty Okyere-ManuPattamukkil AbrahamLubbe WeisnerModiehi Helen MosalaSibongile TshabalalaJanine ScholefieldJuan Eduardo Resendiz-GalvanNeil A. MartinsonEbrahim Variava1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa2Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa3Bioengineering and Integrated Genomics Group, Council for Scientific and Industrial Research, Pretoria, South Africa4Johns Hopkins University Center for Tuberculosis Research, Division of Infectious Diseases, School of Medicine, Baltimore, Maryland, USA5Department of Internal Medicine, University of the Witwatersrand, Klerksdorp/Tshepong Hospital Complex North-West Province, Klerksdorp-Tshepong, South Africa, James E. Leggett
Antimicrobial Agents And Chemotherapy, 10.04.2024
Tilføjet 10.04.2024
15
Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial
Clinical Infectious Diseases, 10.04.2024
Tilføjet 10.04.2024
Abstract Background Children living with HIV(CLWH) are at high risk of tuberculosis(TB) and face poor outcomes, despite antiretroviral treatment(ART). We evaluated outcomes in CLWH and HIV-uninfected children treated for non-severe TB in the SHINE trial.Methods SHINE was a randomized trial that enrolled children aged
Læs mere
Tjek på PubMed
16
Incipient tuberculosis: a comprehensive overview
Infection, 9.04.2024
Tilføjet 9.04.2024
Abstract In the context of the evolving global health landscape shaped by the COVID-19 pandemic, tuberculosis (TB) is gaining renewed attention as a reemerging threat even in low-endemic countries. Immunological tests such as the tuberculin skin test (TST) and interferon-gamma release assay (IGRA) are pivotal in identifying tuberculosis infection (TBI). However, their inability to distinguish between past and ongoing infection poses a diagnostic challenge, possibly leading to the unnecessary treatment of a significant portion of the population with potential side effects. This review delves into the concept of incipient tuberculosis (ITB), a dynamic, presymptomatic stage characterized by heightened Mycobacterium tuberculosis complex (MTC) metabolic activity and replication that result in minimal radiological changes, signifying a transitional state between TBI and TB. Key focus areas include epidemiological factors, underlying pathogenesis, imaging findings, and the ongoing challenges in the identification of individuals with ITB through the development of new biomarkers and the use of whole-genome sequencing-based analyses to implement early treatment strategies.
Læs mere
Tjek på PubMed
17
Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis
Husain PoonawalaYu ZhangSravya KuchibhotlaAnna G. GreenDaniela Maria CirilloFederico Di MarcoAndrea SpitlaeriPaolo MiottoMaha R. Farhat1Department of Medicine and Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts, USA2Department of Medicine and Department of Anatomic and Clinical Pathology, Tufts University School of Medicine, Boston, Massachusetts, USA3Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, Massachusetts, USA4Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA5Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA6Harvard College, Cambridge, Massachusetts, USA7Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy8Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy9Department of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Sean Wasserman
Antimicrobial Agents And Chemotherapy, 9.04.2024
Tilføjet 9.04.2024
18
Public health surveillance through community health workers: a scoping review of evidence from 25 low-income and middle-income countries
Alhassan, J. A. K., Wills, O.
BMJ Open, 6.04.2024
Tilføjet 6.04.2024
BackgroundThe last 3 years have witnessed global health challenges, ranging from the pandemics of COVID-19 and mpox (monkeypox) to the Ebola epidemic in Uganda. Public health surveillance is critical for preventing these outbreaks, yet surveillance systems in resource-constrained contexts struggle to provide timely disease reporting. Although community health workers (CHWs) support health systems in low-income and middle-income countries (LMICs), very little has been written about their role in supporting public health surveillance. This review identified the roles, impacts and challenges CHWs face in public health surveillance in 25 LMICs. MethodsWe conducted a scoping review guided by Arksey and O’Malley’s framework. We exported 1,156 peer-reviewed records from Embase, Global Health and PubMed databases. After multiple screenings, 29 articles were included in the final review. ResultsCHWs significantly contribute to public health surveillance in LMICs including through contact tracing and patient visitation to control major infectious diseases such as HIV/AIDS, malaria, tuberculosis, Ebola, neglected tropical diseases and COVID-19. Their public health surveillance roles typically fall into four main categories including community engagement; data gathering; screening, testing and treating; and health education and promotion. The use of CHWs in public health surveillance in LMICs has been impactful and often involves incorporation of various technologies leading to improved epidemic control and disease reporting. Nonetheless, use of CHWs can come with four main challenges including lack of education and training, lack of financial and other resources, logistical and infrastructural challenges as well as community engagement challenges. ConclusionCHWs are important stakeholders in surveillance because they are closer to communities than other healthcare workers. Further integration and training of CHWs in public health surveillance would improve public health surveillance because CHWs can provide health data on ‘hard-to-reach’ populations. CHWs’ work in public health surveillance would also be greatly enhanced by infrastructural investments.
Læs mere
Tjek på PubMed
19
Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus
Tianlu TengSuting ChenFengmin HuoJunnan JiaLiping ZhaoGuanglu JiangFen WangNaihui ChuHairong Huang1Department of Respiratory and Critical Care Medicine, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China2National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China3Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China, Sean Wasserman
Antimicrobial Agents And Chemotherapy, 4.04.2024
Tilføjet 4.04.2024
20
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits
Meenal DattaLaura E. ViaVéronique DartoisDanielle M. WeinerMatthew ZimmermanFirat KayaApril M. WalkerJoel D. FleegleIsaac D. RapleeColton McNinchMaksym ZarodniukWalid S. KamounChangli YueAshwin S. KumarSonu SubudhiLei XuClifton E. BarryRakesh K. JainaDepartment of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, IN 46556bEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114cTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD 20892dCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110eHackensack Meridian School of Medicine, Hackensack Meridian Health, Nutley, NJ 07110fTuberculosis Imaging Program, Division of Intramural Research, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD 20892gBioinformatics and Computational Bioscience Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892
Proceedings of the National Academy of Sciences, 4.04.2024
Tilføjet 4.04.2024
21
Tuberculosis disease in immunocompromised children and adolescents: a pTBnet multi-centre case-control study
Clinical Infectious Diseases, 4.04.2024
Tilføjet 4.04.2024
Abstract Background In high-resource settings the survival of immunocompromised (IC) children has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools and outcome of IC children with TB in Europe.Methods Multicentre, matched case-control study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), capturing TB cases
Læs mere
Tjek på PubMed
22
Estimating the Potential Public Health Value of BCG Revaccination
Journal of Infectious Diseases, 4.04.2024
Tilføjet 4.04.2024
Abstract An upcoming trial may provide further evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculosis infection, but its public health value depends on its impact on overall tuberculosis morbidity and mortality, which will remain unknown. Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk). Given the assumed prevention-of-infection efficacy and range in prevention-of-disease efficacy, BCG revaccination may have a positive health impact and be cost-effective. This may be useful when considering future evaluations and implementation of adolescent/adult BCG revaccination.
Læs mere
Tjek på PubMed
23
The plasma kynurenine-to-tryptophan ratio as a biomarker of tuberculosis disease in people living with HIV on antiretroviral therapy: an exploratory nested case–control study
BMC Infectious Diseases, 4.04.2024
Tilføjet 4.04.2024
Abstract Background Non-sputum-based tests are needed to predict or diagnose tuberculosis (TB) disease in people living with HIV (PWH). The enzyme indoleamine 2, 3-dioxygenase-1 (IDO1) is expressed in tuberculoid granuloma and catabolizes tryptophan (Trp) to kynurenine (Kyn). IDO1 activity compromises innate and adaptive immune responses, promoting mycobacterial survival. The plasma Kyn-to-Trp (K/T) ratio is a potential TB diagnostic and/or predictive biomarker in PWH on long-term antiretroviral therapy (ART). Methods We compared plasma K/T ratios in samples from PWH, who were followed up prospectively and developed TB disease after ART initiation. Controls were matched for age and duration of ART. Kyn and Trp were measured at 3 timepoints; at TB diagnosis, 6 months before TB diagnosis and 6 months after TB diagnosis, using ultra performance liquid chromatography combined with mass spectrometry. Results The K/T ratios were higher for patients with TB disease at time of diagnosis (median, 0.086; IQR, 0.069–0.123) compared to controls (0.055; IQR 0.045–0.064; p = 0.006), but not before or after TB diagnosis. K/T ratios significantly declined after successful TB treatment, but increased upon treatment failure. The K/T ratios showed a parabolic correlation with CD4 cell counts in participants with TB (p = 0.005), but there was no correlation in controls. Conclusions The plasma K/T ratio helped identify TB disease and may serve as an adjunctive biomarker for for monitoring TB treatment in PWH. Validation studies to ascertain these findings and evaluate the optimum cut-off for diagnosis of TB disease in PWH should be undertaken in well-designed prospective cohorts. Trial registration ClinicalTrials.gov Identifier: NCT00411983.
Læs mere
Tjek på PubMed
24
The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia
BMC Infectious Diseases, 4.04.2024
Tilføjet 4.04.2024
Abstract Background The emergence of Drug Resistant Tuberculosis (DR-TB) is one of the main public health and economic problems facing the world today. DR-TB affects mostly those in economically productive years and prevents them from being part of the workforce needed for economic growth. The aim of this study was to determine the Clinical Profile and Outcomes of DR-TB in Central Province of Zambia. Methods This was a retrospective cross sectional study that involved a review of records of patients with confirmed DR-TB who were managed at Kabwe Central Hospital’s Multi-Drug Resistant TB (MDR-TB) Ward from the year 2017 to 2021. 183 patients were managed during this period and all were recruited in the study. Data was collected from DR-TB registers and patient files and then entered in SPSS version 22 where all statistical analyses were performed. Results The study revealed that the prevalence of DR-TB among registered TB patients in Central Province was 1.4%. Majority of those affected were adults between the ages of 26 and 45 years (63.9%). The study also found that more than half of the patients were from Kabwe District (60.7%). Other districts with significant number of cases included Kapiri Mposhi 19 (10.4%), Chibombo 12 (6.6%), Chisamba 10 (5.5%), Mumbwa 7 (3.8%) and Mkushi 7 (3.8%). Furthermore, the analysis established that most of the patients had RR-TB (89.6%). 9.3% had MDR-TB, 0.5% had IR-TB and 0.5% had XDR-TB. RR-TB was present in 93.8% of new cases and 88.9% of relapse cases. MDR-TB was present in 6.2% of new cases and 10% of relapse cases. With regard to outcomes of DR-TB, the investigation revealed that 16.9% of the patients had been declared cured, 45.9% had completed treatment, 6% were lost to follow up and 21.3% had died. Risk factors for mortality on multivariate analysis included age 36–45 years (adjusted odds ratio [aOR] 0.253, 95% CI [0.70–0.908] p = 0.035) and male gender (aOR 0.261, 95% CI [0.107–0.638] p = 0.003). Conclusion The research has shown beyond doubt that the burden of DR-TB in Central Province is high. The study recommends putting measures in place that will help improve surveillance, early detection, early initiation of treatment and proper follow up of patients.
Læs mere
Tjek på PubMed
25
[News] Phase 2 trial of a novel tuberculosis drug launched
Ed Holt
The Lancet Microbe, 4.04.2024
Tilføjet 4.04.2024
During the Union World Conference on Lung Health 2023, held in Paris, France, on Nov 15–18, results from preclinical studies and a phase 1 trial of a novel candidate tuberculosis drug were presented. The new compound, named TBAJ-876, belongs to the diarylquinoline class of antibiotics (like bedaquiline).
Læs mere
Tjek på PubMed
26
[Articles] Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda
Emmanuel Musisi, Samuel Wamutu, Willy Ssengooba, Sharifah Kasiinga, Abdulwahab Sessolo, Ingvar Sanyu, Sylvia Kaswabuli, Josephine Zawedde, Patrick Byanyima, Praiscillia Kia, William Muwambi, Divine Tracy Toskin, Edgar Kigozi, Natasha Walbaum, Evelin Dombay, Mate Bonifac Legrady, Kizza David-Martin Ssemambo, Moses Joloba, Davis Kuchaka, William Worodria, Laurence Huang, Stephen H Gillespie, Wilber Sabiiti
The Lancet Microbe, 4.04.2024
Tilføjet 4.04.2024
TB-MBLA has a similar performance to Xpert-Ultra for pretreatment diagnosis of tuberculosis, but is more accurate at detecting and characterising the response to treatment than Xpert-Ultra and standard-of-care smear microscopy.
Læs mere
Tjek på PubMed
27
Gendered gaps to tuberculosis prevention and care in Kenya: a political economy analysis study
Abdullahi, L. H., Oketch, S., Komen, H., Mbithi, I., Millington, K., Mulupi, S., Chakaya, J., Zulu, E. M.
BMJ Open, 3.04.2024
Tilføjet 3.04.2024
BackgroundTuberculosis (TB) remains a public health concern in Kenya despite the massive global efforts towards ending TB. The impediments to TB prevention and care efforts include poor health systems, resource limitations and other sociopolitical contexts that inform policy and implementation. Notably, TB cases are much higher in men than women. Therefore, the political economy analysis (PEA) study provides in-depth contexts and understanding of the gender gaps to access and successful treatment for TB infection. DesignPEA adopts a qualitative, in-depth approach through key informant interviews (KII) and documentary analysis. Setting and participantsThe KIIs were distributed among government entities, academia, non-state actors and community TB groups from Kenya. ResultsThe themes identified were mapped onto the applied PEA analysis framework domains. The contextual and institutional issues included gender concerns related to the disconnect between TB policies and gender inclusion aspects, such as low prioritisation for TB programmes, limited use of evidence to inform decisions and poor health system structures. The broad barriers influencing the social contexts for TB programmes were social stigma and cultural norms such as traditional interventions that negatively impact health-seeking behaviours. The themes around the economic situation were poverty and unemployment, food insecurity and malnutrition. The political context centred around the systemic and governance gaps in the health system from the national and devolved health functions. ConclusionBroad contextual factors identified from the PEA widen the disparity in targeted gender efforts toward men. Following the development of effective TB policies and strategies, it is essential to have well-planned gendered responsive interventions with a clear implementation plan and monitoring system to enhance access to TB prevention and care.
Læs mere
Tjek på PubMed
28
Disseminated Tuberculosis of the Axial Skeleton
American Journal of Tropical Medicine and Hygiene, 3.04.2024
Tilføjet 3.04.2024
Journal Name: The American Journal of Tropical Medicine and Hygiene Volume: 110 Issue: 4 Pages: 623-624
Læs mere
Tjek på PubMed
29
Cardiac Tuberculosis: A Case Series from Ethiopia, Italy, and Uganda and a Literature Review
American Journal of Tropical Medicine and Hygiene, 3.04.2024
Tilføjet 3.04.2024
Journal Name: The American Journal of Tropical Medicine and Hygiene Volume: 110 Issue: 4 Pages: 795-804
Læs mere
Tjek på PubMed
30
The plasma kynurenine-to-tryptophan ratio as a biomarker of tuberculosis disease in people living with HIV on antiretroviral therapy: an exploratory nested case–control study
BMC Infectious Diseases, 3.04.2024
Tilføjet 3.04.2024
Abstract Background Non-sputum-based tests are needed to predict or diagnose tuberculosis (TB) disease in people living with HIV (PWH). The enzyme indoleamine 2, 3-dioxygenase-1 (IDO1) is expressed in tuberculoid granuloma and catabolizes tryptophan (Trp) to kynurenine (Kyn). IDO1 activity compromises innate and adaptive immune responses, promoting mycobacterial survival. The plasma Kyn-to-Trp (K/T) ratio is a potential TB diagnostic and/or predictive biomarker in PWH on long-term antiretroviral therapy (ART). Methods We compared plasma K/T ratios in samples from PWH, who were followed up prospectively and developed TB disease after ART initiation. Controls were matched for age and duration of ART. Kyn and Trp were measured at 3 timepoints; at TB diagnosis, 6 months before TB diagnosis and 6 months after TB diagnosis, using ultra performance liquid chromatography combined with mass spectrometry. Results The K/T ratios were higher for patients with TB disease at time of diagnosis (median, 0.086; IQR, 0.069–0.123) compared to controls (0.055; IQR 0.045–0.064; p = 0.006), but not before or after TB diagnosis. K/T ratios significantly declined after successful TB treatment, but increased upon treatment failure. The K/T ratios showed a parabolic correlation with CD4 cell counts in participants with TB (p = 0.005), but there was no correlation in controls. Conclusions The plasma K/T ratio helped identify TB disease and may serve as an adjunctive biomarker for for monitoring TB treatment in PWH. Validation studies to ascertain these findings and evaluate the optimum cut-off for diagnosis of TB disease in PWH should be undertaken in well-designed prospective cohorts. Trial registration ClinicalTrials.gov Identifier: NCT00411983.
Læs mere
Tjek på PubMed
31
Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini
Ernest Peresu, Diana De Graeve, J. Christo Heunis, N. Gladys Kigozi
PLoS One Infectious Diseases, 3.04.2024
Tilføjet 3.04.2024
by Ernest Peresu, Diana De Graeve, J. Christo Heunis, N. Gladys Kigozi Background We compared the cost-consequence of a home-based multidrug-resistant tuberculosis (MDR-TB) model of care, based on task-shifting of directly observed therapy (DOT) and MDR-TB injection administration to lay health workers, to a routine clinic-based strategy within an established national TB programme in Eswatini. Methods Data on costs and effects of the two ambulatory models of MDR-TB care was collected using documentary data and interviews in the Lubombo and Shiselweni regions of Eswatini. Health system, patient and caregiver costs were assessed in 2014 in US$ using standard methods. Cost-consequence was calculated as the cost per patient successfully treated. Results In the clinic-based and home-based models of care, respectively, a total of 96 and 106 MDR-TB patients were enrolled in 2014, with treatment success rates of 67.8% and 82.1%. Health system costs per patient treated were slightly lower in the home-based strategy (US$19 598) compared to the clinic-based model (US$20 007). The largest costs in both models were for inpatient care, administration of DOT and injectable treatment, and drugs. Costs incurred by patients and caregivers were considerably higher in the clinic-based model of care due to the higher direct travel costs to the nearest clinic to receive DOT and injections daily. In total, MDR patients in the clinic-based strategy incurred average costs of US$670 compared to US$275 for MDR-TB patients in the home-based model. MDR-TB patients in the home-based programme, where DOT and injections was provided in their homes, only incurred out-of-pocket travel expenses for monthly outpatient treatment monitoring visits averaging US$100. The cost per successfully treated patient was US$31 106 and US$24 157 in the clinic-based and home-based models of care, respectively. The analysis showed that, in addition to the health benefits, direct and indirect costs for patients and their caregivers were lower in the home-based care model. Conclusion The home‐based strategy used less resources and generated substantial health and economic benefits, particularly for patients and their caregivers, and decision makers can consider this approach as an alternative to expand and optimise MDR-TB control in resource-limited settings. Further research to understand the appropriate mix of treatment support components that are most important for optimal clinical and public health outcomes in the ambulatory home-based model of MDR-TB care is necessary.
Læs mere
Tjek på PubMed
32
The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia
BMC Infectious Diseases, 1.04.2024
Tilføjet 1.04.2024
Abstract Background The emergence of Drug Resistant Tuberculosis (DR-TB) is one of the main public health and economic problems facing the world today. DR-TB affects mostly those in economically productive years and prevents them from being part of the workforce needed for economic growth. The aim of this study was to determine the Clinical Profile and Outcomes of DR-TB in Central Province of Zambia. Methods This was a retrospective cross sectional study that involved a review of records of patients with confirmed DR-TB who were managed at Kabwe Central Hospital’s Multi-Drug Resistant TB (MDR-TB) Ward from the year 2017 to 2021. 183 patients were managed during this period and all were recruited in the study. Data was collected from DR-TB registers and patient files and then entered in SPSS version 22 where all statistical analyses were performed. Results The study revealed that the prevalence of DR-TB among registered TB patients in Central Province was 1.4%. Majority of those affected were adults between the ages of 26 and 45 years (63.9%). The study also found that more than half of the patients were from Kabwe District (60.7%). Other districts with significant number of cases included Kapiri Mposhi 19 (10.4%), Chibombo 12 (6.6%), Chisamba 10 (5.5%), Mumbwa 7 (3.8%) and Mkushi 7 (3.8%). Furthermore, the analysis established that most of the patients had RR-TB (89.6%). 9.3% had MDR-TB, 0.5% had IR-TB and 0.5% had XDR-TB. RR-TB was present in 93.8% of new cases and 88.9% of relapse cases. MDR-TB was present in 6.2% of new cases and 10% of relapse cases. With regard to outcomes of DR-TB, the investigation revealed that 16.9% of the patients had been declared cured, 45.9% had completed treatment, 6% were lost to follow up and 21.3% had died. Risk factors for mortality on multivariate analysis included age 36–45 years (adjusted odds ratio [aOR] 0.253, 95% CI [0.70–0.908] p = 0.035) and male gender (aOR 0.261, 95% CI [0.107–0.638] p = 0.003). Conclusion The research has shown beyond doubt that the burden of DR-TB in Central Province is high. The study recommends putting measures in place that will help improve surveillance, early detection, early initiation of treatment and proper follow up of patients.
Læs mere
Tjek på PubMed
33
Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial
Journal of Infectious Diseases, 1.04.2024
Tilføjet 1.04.2024
Abstract Background H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB.Methods 22 adults confirmed to be Mtb negative (by 2 GeneXpert tests or 2 sputum cultures) after four-five months of TB treatment, and not more than 28 days after completion of TB treatment, were randomized to receive two doses of H56:IC31 (5 mg H56:500 nmol IC31; N=16) or placebo (N=6) 56 days apart. Participants were followed for 420 days for safety and immunogenicity.Results H56:IC31 vaccination was associated with an acceptable safety profile, consisting mostly of mild self-limited injection site reactions. No serious adverse events, and no vaccine-related severe adverse events, were reported. H56:IC31 induced a CD4+ T-cell response for Ag85B and ESAT-6, with ESAT-6 being immunodominant, which persisted through six months after the last vaccination. There was some evidence of CD8+ T-cell responses for both Ag85B and ESAT-6, but to a lesser extent than CD4+ responses.Conclusions H56:IC31 was associated with an acceptable safety profile, and induced a predominant CD4+ T-cell response, in adults recently treated for drug-susceptible, uncomplicated pulmonary TB.Trial registration ClinicalTrials.gov, NCT02375698
Læs mere
Tjek på PubMed
34
Mortality of children and adolescents co-infected with tuberculosis and HIV: a systematic review and meta-analysis
Hu, Fei-Hong; Tang, Xiao-Lei; Ge, Meng-Wei; Jia, Yi-Jie; Zhang, Wan-Qing; Tang, Wen; Shen, Lu-Ting; Du, Wei; Xia, Xiao-Peng; Chen, Hong-Lin
AIDS, 30.03.2024
Tilføjet 30.03.2024
Objective: Children and adolescents with HIV infection are well-known to face a heightened risk of tuberculosis. However, the exact mortality rates and temporal trends of those with HIV-TB co-infection remain unclear. We aimed to identify the overall mortality and temporal trends within this population. Methods: PubMed, Web of Science, and Embase were employed to search for publications reporting on the mortality rates of children and adolescents with HIV-TB co-infection from inception to March 2, 2024. The outcome is the mortality rate for children and adolescents with HIV-TB co-infection during the follow-up period. In addition, we evaluate the temporal trends of mortality. Results: During the follow-up period, the pooled mortality was 16% (95% CI 13–20). Single infection of either HIV or TB exhibit lower mortality rates (6% and 4%, respectively). We observed elevated mortality risks among individuals aged less than 12 months, those with EPTB, poor adherence to ART, and severe immunosuppression. In addition, we observed a decreasing trend in mortality before 2008 and an increasing trend after 2008, although the trends were not statistically significant (P = 0.08 and 0.2 respectively). Conclusions: Children and adolescents with HIV-TB co-infection bear a significant burden of mortality. Timely screening, effective treatment, and a comprehensive follow-up system contribute to reducing the mortality burden in this population. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere
Tjek på PubMed
35
BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination
Abebe Fromsa, Katriina Willgert, Sreenidhi Srinivasan, Getnet Mekonnen, Wegene Bedada, Balako Gumi, Matios Lakew, Biniam Tadesse, Berecha Bayissa, Asegedech Sirak, Musse Girma Abdela, Solomon Gebre, Tesfaye Chibssa, Maroudam Veerasami, H. Martin Vordermeier, Douwe Bakker, Stefan Berg, Gobena Ameni, Nick Juleff, Mart C. M. de Jong, James Wood, Andrew Conlan, Vivek Kapur
Science, 29.03.2024
Tilføjet 29.03.2024
36
Vaccines to control tuberculosis in cattle
Anita L. Michel
Science, 29.03.2024
Tilføjet 29.03.2024
37
Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection—California, 2016–2020
Clinical Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background Improved epidemiologic and treatment data for active tuberculosis (TB) with chronic hepatitis B virus (cHBV) infection might inform and encourage screening and vaccination programs focused on persons at risk of having both conditions.Methods We matched the California Department of Public Health TB registry during 2016–2020 to the cHBV registry using probabilistic matching algorithms. We used chi-square analysis to compare the characteristics of persons with TB and cHBV with those with TB only. We compared TB treatment outcomes between these groups using modified Poisson regression models. We calculated the time between reporting of TB and cHBV diagnoses for those with both conditions.Results We identified 8,435 persons with TB, including 316 (3.7%) with cHBV. Among persons with TB and cHBV, 256 (81.0%) were non-U.S.-born Asian vs 4,186 (51.6%) with TB only (P 60 days after cHBV (median 3,411 days).Conclusion Persons with TB and cHBV were found more frequently in certain groups compared with TB only, and infrequently had their conditions diagnosed together. This highlights an opportunity to improve screening and treatment of TB and cHBV in those at high risk for coinfection.
Læs mere
Tjek på PubMed
38
Progress and challenges in achieving tuberculosis elimination in India by 2025: A systematic review and meta-analysis
Abhishek Padhi, Ashwini Agarwal, Mayuri Bhise, Anil Chaudhary, Krupal Joshi, C. D. S. Katoch
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Abhishek Padhi, Ashwini Agarwal, Mayuri Bhise, Anil Chaudhary, Krupal Joshi, C. D. S. Katoch Background Tuberculosis (TB) continues to pose a significant public health challenge in India, which is home to one of the highest TB burdens worldwide. This systematic review and meta-analysis will aim to synthesize the anticipated progress and potential challenges in achieving TB elimination in India by 2025. Methods A comprehensive search will be conducted across multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant studies. The eligibility criteria will encompass individuals diagnosed with TB in India, interventions targeting TB treatment, prevention, or control, and various comparator groups. Outcomes of interest will include incidence reduction, mortality rate, treatment success rate, barriers to TB care, and more. Both quantitative and qualitative data will be synthesized, and the risk of bias will be assessed using established tools. Outcomes The review is expected to provide a holistic understanding of the TB landscape in India, highlighting the effective interventions and potential challenges in the journey towards TB elimination. Conclusions While it is anticipated that significant progress will be made in the fight against TB in India, challenges are likely to persist. This review will offer a comprehensive roadmap for researchers, policymakers, and healthcare professionals, emphasizing the importance of continued efforts, innovative strategies, and a multi-pronged approach in achieving the goal of TB elimination in India by 2025.
Læs mere
Tjek på PubMed
39
The use of Kudoh method for culture of Mycobacterium tuberculosis and Mycobacterium africanum in The Gambia
Tijan Jobarteh, Jacob Otu, Ensa Gitteh, Francis S. Mendy, Tutty Isatou Faal-Jawara, Boatema Ofori-Anyinam, Binta Sarr, Abi Janet Riley, Abigail Ayorinde, Bouke C. de Jong, Beate Kampmann, Ousman Secka, Florian Gehre
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Tijan Jobarteh, Jacob Otu, Ensa Gitteh, Francis S. Mendy, Tutty Isatou Faal-Jawara, Boatema Ofori-Anyinam, Binta Sarr, Abi Janet Riley, Abigail Ayorinde, Bouke C. de Jong, Beate Kampmann, Ousman Secka, Florian Gehre Background Mycobacterium tuberculosis culturing remains the gold standard for laboratory diagnosis of tuberculosis. Tuberculosis remains a great public health problem in developing countries like The Gambia, as most of the methods currently used for bacterial isolation are either time-consuming or costly. Objective To evaluate the Kudoh swab method in a West African setting in Gambia, with a particular focus on the method’s performance when culturing Mycobacterium africanum West Africa 2 (MAF2) isolates. Method 75 sputum samples were collected in the Greater Banjul Area and decontaminated in parallel with both the standard N-acetyl-L-Cysteine-NaOH (NALC-NaOH) and the Kudoh swab method in the TB diagnostics laboratory in the Medical Research Council Unit The Gambia between 30th December 2017 and 25th February 2018. These samples were subsequently cultured on standard Löwenstein-Jensen and Modified Ogawa media respectively and incubated at 37°C for mycobacterial growth. Spoligotyping was done to determine if the decontamination and culture methods compared could equally detect Mycobacterium tuberculosis, Mycobacterium africanum West Africa 1 and Mycobacterium africanum West Africa 2. Result Among the 50 smear positives, 35 (70%) were culture-positive with Kudoh and 32 (64%) were culture positive with NALC-NaOH, whilst 7(28%) of the 25 smear negative samples were culture positive with both methods (Table 2). There was no significant difference in recovery between both methods (McNemar’s test, p-value = 0.7003), suggesting that the overall positivity rate between the two methods is comparable. There were no differences in time-to-positivity or contamination rate between the methods. However, Kudoh yielded positive cultures that were negative on LJ and vice versa. All findings were irrespective of mycobacterial lineages. Conclusion The Kudoh method has comparable sensitivity to the NALC-NaOH method for detecting Mycobacterium tuberculosis complex isolates. It is easy to perform and could be an add on option for mycobacterial culture in the field in The Gambia, since it requires less biosafety equipment.
Læs mere
Tjek på PubMed
40
Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin
Praharshinie RupasingheAzka AshrafNadia BarredaShafiqua ParveenMuhammad ZubairRoger CalderonSunil AsifNilma HiraniLayila ChingisovaAtang BulanePham Thu HangDoan Thu HaElisa ArdizzoniNazia KursheedWillem Bram De RijkLeen RigoutsLorenzo GuglielmettiCarol MitnickBouke C. de Jong1Unit of Mycobacteriology, Institute of Tropical Medicine, Antwerp, Belgium2Department of Biomedical Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium3The Indus Hospital laboratory, Karachi, Pakistan4Socios en Salud, Lima, Peru5Department of Microbiology, Sir JJ Hospital, Mumbai, India6National Tuberculosis Reference Lab, Almaty, Kazakhstan7Center for Tuberculosis, National Institute of Communicable Diseases, Mohakhali, South Africa8Regional Tuberculosis Reference Lab, Ho Chi Minh, Vietnam9National Tuberculosis Reference Lab, Hanoi, Vietnam10Medical Department, MSF, Paris, France11Sorbonne University, Centre d’Immunologie et des Maladies Infectieuses (Cimi-Paris), Paris, France12AP-HP, Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, Paris, France13Brigham and Women's Hospital, Boston, Massachusetts, USA14Partners In Health, Boston, Massachusetts, USA15Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA, Sean Wasserman
Antimicrobial Agents And Chemotherapy, 27.03.2024
Tilføjet 27.03.2024
41
[Editorial] Ending tuberculosis: ways forward
The Lancet Respiratory Medicine
Lancet Respiratory Medicine, 27.03.2024
Tilføjet 27.03.2024
Around 25 000 people die from tuberculosis every week, despite the disease being curable. Progress in reducing tuberculosis morbidity and mortality is hindered by inadequate access to testing and treatment, with at least 40% of those infected remaining undiagnosed. Our 2022 Series, highlighted the huge scale of the problem, exacerbated by COVID-19, and outlined priorities for rapid restoration of tuberculosis services. In a 2023 Editorial, we discussed the need for substantial investment in vaccines and research to improve health-care services in LMICs.
Læs mere
Tjek på PubMed
42
[News] Tuberculosis, conflict, and displacement
Talha Burki
Lancet Respiratory Medicine, 27.03.2024
Tilføjet 27.03.2024
In places where conflict and displacement are a constant threat, Médecins Sans Frontières (MSF) has a straightforward way of ensuring that the people being treated for tuberculosis do not leave without their medication. MSF keeps a stock of so-called runaway kits containing sufficient drugs for each patient to finish their course. “If it seems likely that people are going to be displaced, we hand out the kits”, Animesh Sinha (HIV/TB/Hepatitis Advisor, MSF, London, UK) told The Lancet Respiratory Medicine.
Læs mere
Tjek på PubMed
43
Correction: Characterisation of ATP-Dependent Mur Ligases Involved in the Biogenesis of Cell Wall Peptidoglycan in Mycobacterium tuberculosis
Tulika Munshi, Antima Gupta, Dimitrios Evangelopoulos, Juan David Guzman, Simon Gibbons, Nicholas H. Keep, Sanjib Bhakta
PLoS One Infectious Diseases, 27.03.2024
Tilføjet 27.03.2024
by Tulika Munshi, Antima Gupta, Dimitrios Evangelopoulos, Juan David Guzman, Simon Gibbons, Nicholas H. Keep, Sanjib Bhakta
Læs mere
Tjek på PubMed
44
Tuberculosis disease is associated with elevated plasma ribonuclease activity in antiretroviral treatment-naïve people with HIV
Journal of Infectious Diseases, 26.03.2024
Tilføjet 26.03.2024
Abstract Background The role of ribonucleases in tuberculosis (TB) among people with HIV (PWH) is unknown. We explored ribonuclease activity in plasma from PWH with and without TB.Methods Participants were identified from a cohort of treatment-naïve PWH in Ethiopia who had been classified for TB disease (HIV+/TB + or HIV+/TB-). Ribonuclease activity in plasma was investigated by quantification of synthetic spike-in RNAs using sequencing and qPCR, and by a specific ribonuclease activity assay. Quantification of ribonuclease 1, 2, 3, 6, 7 and T2 proteins was performed by ELISA. Ribonuclease activity and protein concentrations were correlated with markers of TB and HIV disease severity and with concentrations of inflammatory mediators.Results Ribonuclease activity was significantly higher in plasma of HIV+/TB + (n = 51) compared to HIV+/TB- (n = 78), causing reduced stability of synthetic spike-in RNAs. concentrations of ribonucleases 2, 3 and T2 were also significantly increased in HIV+/TB + compared to HIV+/TB-. Ribonuclease activity was correlated with HIV viral load, and inversely correlated with CD4 count, mid-upper arm circumference and body mass index. Moreover, ribonuclease activity correlated with concentrations of interleukin-27, kynurenine/tryptophan ratio and procalcitonin.Conclusion PWH with TB disease have elevated plasma ribonuclease activity, which is also associated with HIV severity and systemic inflammation.
Læs mere
Tjek på PubMed
45
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: A retrospective cohort study
Clinical Infectious Diseases, 25.03.2024
Tilføjet 25.03.2024
Abstract Background In 2019, the South African tuberculosis program replaced ethionamide with linezolid as a part of an all-oral 9-month regimen. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017.Method This retrospective cohort study included patients treated for multi-drug resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 Jan to 31 Dec 2017 and from 1 Jan to 31 Dec 2019. The cohort treated with a 9-month regimen containing ethionamide for four months, was compared with a cohort treated with a 9-month regimen containing linezolid for two months. The regimens were otherwise identical. Inverse probability weighting of propensity scores was used to adjust for potential confounding. A log-binomial regression model was used to estimate adjusted relative risk (aRR) comparing 24-month outcomes between cohorts including treatment success, death, loss to follow up, and treatment failure. Adverse event data were available for the linezolid cohort.Findings 817 patients were included in the cohort receiving ethionamide and 4244 in the cohort receiving linezolid. No evidence for a difference was observed between linezolid and ethionamide regimens for treatment success (aRR = 0·96, 95%CI 0·91-1·01), death (aRR = 1·01, 95%CI 0·87-1·17) or treatment failure (aRR = 0·87, 95%CI 0·44-1·75). Loss to follow up was more common in the linezolid group, although estimates were imprecise (aRR = 1·22, 95%CI 0·99-1·50).Interpretation No significant differences in treatment success and survival were observed with substitution of linezolid for ethionamide as a part of an all-oral 9-month regimen. Linezolid is an acceptable alternative to ethionamide in this shorter regimen for treatment of multi-drug resistant/rifampicin resistant tuberculosis.
Læs mere
Tjek på PubMed
46
Modelling the preventive treatment under media impact on tuberculosis: A comparison in four regions of China
Infectious Disease Modelling, 13.02.2024
Tilføjet 13.02.2024
Publication date: Available online 12 February 2024 Source: Infectious Disease Modelling Author(s): Jun Zhang, Yasuhiro Takeuchi, Yueping Dong, Zhihang Peng
Læs mere
Tjek på PubMed
47
Analysis of the impacts of treatments in a HIV/AIDS and Tuberculosis co-infected population under random perturbations
Infectious Disease Modelling, 16.11.2023
Tilføjet 16.11.2023
Publication date: Available online 15 November 2023 Source: Infectious Disease Modelling Author(s): Olusegun Michael Otunuga
Læs mere
Tjek på PubMed